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Abstract: DPYD genotyping prior to fluoropyrimidine treatment is increasingly implemented in
clinical care. Without phasing information (i.e., allelic location of variants), current genotype-based
dosing guidelines cannot be applied to patients carrying multiple DPYD variants. The primary
aim of this study is to examine diagnostic and therapeutic strategies for fluoropyrimidine
treatment of patients carrying multiple DPYD variants. A case series of patients carrying multiple
DPYD variants is presented. Different genotyping techniques were used to determine phasing
information. Phenotyping was performed by dihydropyrimidine dehydrogenase (DPD) enzyme
activity measurements. Publicly available databases were queried to explore the frequency and
phasing of variants of patients carrying multiple DPYD variants. Four out of seven patients carrying
multiple DPYD variants received a full dose of fluoropyrimidines and experienced severe toxicity.
Phasing information could be retrieved for four patients. In three patients, variants were located
on two different alleles, i.e., in trans. Recommended dose reductions based on the phased genotype
differed from the phenotype-derived dose reductions in three out of four cases. Data from publicly
available databases show that the frequency of patients carrying multiple DPYD variants is low
(< 0.2%), but higher than the frequency of the commonly tested DPYD*13 variant (0.1%). Patients
carrying multiple DPYD variants are at high risk of developing severe toxicity. Additional analyses
are required to determine the correct dose of fluoropyrimidine treatment. In patients carrying
multiple DPYD variants, we recommend that a DPD phenotyping assay be carried out to determine a
safe starting dose.
Keywords: pharmacogenomics; pharmacogenetics; genotype; phenotype; alleles; precision medicine
1. Introduction
Fluoropyrimidines (including 5-fluorouracil (5-FU) and capecitabine) are the cornerstone of
treatment for various types of cancer and are used by millions of patients worldwide each year [1–3].
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However, up to one-third of treated patients experience severe toxicity (Common Terminology Criteria
for Adverse Events (CTC-AE) grade ≥ 3), such as diarrhea, hand–foot syndrome, or mucositis upon
treatment with fluoropyrimidines [4,5]. These adverse events can lead to mortality in approximately 1%
of patients who experience severe toxicity [4,6]. Dihydropyrimidine dehydrogenase (DPD) is the key
enzyme in the metabolism of 5-FU and its decreased activity is strongly associated with toxicity [7,8].
Variants in DPYD, the gene encoding DPD, can lead to decreased DPD enzyme activity [9–12].
Prospective DPYD genotyping of four main DPYD variants followed by dose reductions in patients
carrying any of these four DPYD variants is safe, cost-effective, and feasible in clinical practice [13–15].
These DPYD variants are DPYD*2A (rs3918290, c.1905+1G>A, IVS14+1G>A); DPYD*13 (rs55886062,
c.1679T>G, I560S); c.1236G>A/HapB3 (rs56038477, E412E); and c.2846A>T (rs67376798, D949V).
For these four variants, convincing evidence has been provided warranting implementation in clinical
practice [4,5,12,15–17].
An increasing number of hospitals apply prospective DPYD genotyping when treating patients
with fluoropyrimidines [18]. Individual dosing guidelines for the abovementioned four DPYD
variants are provided by the Dutch Pharmacogenetics Working Group (DPWG) and the Clinical
Pharmacogenetics Implementation Consortium (CPIC) [19,20]. Dosing guidelines are based on the
expected remaining DPD enzyme activity and can be applied to patients who are heterozygous
carriers of a single DPYD variant. For homozygous DPYD variant allele carriers (two identical
variants) and compound heterozygous DPYD variant allele carriers (two or more different variants),
dosing guidelines are not yet available (or treatment with an alternative drug is advised), although safe
treatment with low-dose fluoropyrimidines in these homozygous DPYD patients was demonstrated
by a recent case series [21].
Patients who carry multiple variants (compound heterozygous) can carry the variants on a
single allele (in cis) or on different alleles (in trans). In the first case, one functionally active allele
remains, whereas in the latter case, both alleles are affected, which may result in a proportionally
decreased enzyme activity (Figure 1). With currently used genotyping techniques, the allelic location
of variants (phasing) cannot be determined. This uncertainty hampers adequate interpretation of
the pharmacogenetic test result in compound heterozygous patients and makes it impossible to give
an appropriate dose recommendation based on the genotype alone. Since it is likely that in the
future, even more DPYD variants will be tested, the probability of finding compound heterozygous
DPYD variant allele carriers will increase. The aims of this study are to examine diagnostic and
therapeutic strategies for fluoropyrimidine treatment of patients carrying multiple DPYD variants
and the frequency and phasing of variants of compound heterozygous DPYD patients in publicly
available databases.
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Figure 1. Illustration of zygosity and clinical interpretations. Black stars represent variants; boxes 
represent alleles. A wild-type patient carries no variants, resulting in normal-activity alleles (green). 
A heterozygous patient carries one variant, resulting in one reduced or inactive allele (red) and one 
active allele (green). A partly reduced enzyme activity is expected, since there is still one active allele 
left. For homozygous patients, both variants result in a reduced or inactive allele (red). Depending on 
the effect of the variants on the protein, a reduced or absent enzyme activity is expected. Compound 
heterozygous patients can carry variants on different alleles (in trans) or on one allele (in cis), 
resulting in differences in enzyme function, either like that of a heterozygous patient or a 
homozygous patient.  
2. Materials and Methods 
In this study, we present seven compounds heterozygous DPYD variant allele carriers as 
clinical cases. In addition, we have performed in silico research in publicly available databases. 
2.1. Patients 
Data and DNA from patient cases carrying multiple DPYD variants were collected. Patients 
were identified either after development of severe toxicity from fluoropyrimidine-containing 
therapy, by additional retrospective genotyping in a clinical trial (clinicaltrials.gov identifier 
NCT00838370, [13]), or prior to treatment in routine clinical care. The study was reviewed and 
approved by the institutional review board of the Leiden University Medical Centre (LUMC, 
G18.015). Patient data from the electronic medical records was handled following the codes of 
proper use and proper conduct in the self-regulatory codes of conduct [22]. Toxicity to 
fluoropyrimidine-containing therapy was graded by the treating physicians using the National 
Cancer Institute CTC-AE version 4.03 [23], and severe fluoropyrimidine-induced toxicity was 
defined as CTC-AE grade ≥ 3. In some cases, additional patient material to determine the phasing of 
the DPYD variants was collected. In these cases, additional patient consent was obtained. 
2.2. Dihydropyrimidine Dehydrogenase Enzyme Activity Measurements 
For all patients, DPD enzyme activity was determined. This could be either prior to treatment 
or retrospectively after the occurrence of severe toxicity. DPD enzyme activity measurement in 
peripheral blood mononuclear cells (PBMCs) [24,25] was used as a reference to assess DPD activity, 
and has been used previously to determine dosages in DPYD variant-carrying patients [21,26]. A 
validated method [27] was used, containing radiolabeled thymine as a substrate and consisting of 
Figure 1. Illustration of zygosity and clinical interpretations. Black stars represent variants; boxes
represent alleles. A wild-type patient carries no variants, resulting in normal-activity alleles (green).
A heterozygous patient carries one variant, resulting in one reduced or inactive allele (red) and one
active allele (green). A partly reduced enzyme activity is expected, since there is still one active allele
left. For homozygous patients, both variants result in a reduced or inactive allele (red). Depending on
the effect of the variants on the protein, a reduced or absent enzyme activity is expected. Compound
heterozygous patients can carry variants on different alleles (in trans) or on one allele (in cis), resulting
in differences in enzyme function, either like that of a heterozygous patient or a homozygous patient.
2. Mat rials and Methods
In this study, we present seven compounds heterozygous DPYD variant allele carriers as clinical
cases. In addition, we have performed in silico research in publicly available databases.
2.1. Patients
Data and DNA from patient cases carrying multiple DPYD variants were collected. Patients
were identified either after development of severe toxicity from fluoropyrimidine-containing therapy,
by additional retrospective genotyping in a clinical trial (clinicaltrials.gov identifier NCT00838370, [13]),
or prior o treatment in utine cli ical care. The study was reviewed and pprov d by the institutional
review board of the Leiden Uni rsity Medical Centre (LUMC, G18.015). Patient data from the
electronic medical records was handled following the codes of proper use and proper conduct in the
self-regulatory codes f conduct [22]. Toxicity to fluoropyrimidine-containing therapy was graded
by the treating physicians using the Nation l Cancer Institute CTC-AE version 4.03 [23], and severe
fluoropyrimid ne-induced toxicity was defined as CTC-AE grade≥ 3. In some cases, additional patient
material to determine the phasing of the DPYD variants was collected. In these cases, additional
patient consent was obtai ed.
2.2. Dihydropyrimidine Dehydrogenase Enzyme Activity Measurements
For all patients, DPD enzyme activity was determined. This could be either prior to treatment
or retrospectively after the occurrence of severe toxicity. DPD enzyme activity measurement in
peripheral blood mononuclear cells (PBMCs) [24,25] was used as a reference to assess DPD activity,
and has been used previousl to determine dosages i DPYD variant-carrying patients [21,26].
A validated method [27] was used, containing radi labeled thymi e as a substrate and consisting
of high-performance liq id chromatography (HPLC) with online radioisotope detection using
liquid scintillation counting. N rmal values for healthy volunteers are 9.9 ± 2.8 nmol/(mg×h),
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for DPD-deficient patients are 4.8 ± 1.7 nmol/(mg×h), and reference values range from 5.9 to
14 nmol/(mg×h) [28]. Dose reductions based on DPD enzyme activity were performed in a one-to-one
ratio, as was previously described by Henricks et al. [21]. Thereafter, toxicity-guided dosing was used.
2.3. Molecular Methods for Estimation of Phasing
In regard to the size of the DPYD gene, the location of the variants, and the material available
(DNA, RNA) from the patients, three molecular methods to determine the phasing of the variants could
be used in this study. In four patients, we could execute one or more of these methods. These methods
are explained and illustrated in the supplementary material (Figure S1). Details on these techniques
have been published elsewhere [29–31].
2.4. Frequencies of Compound Heterozygous DPYD Carriers
To investigate the incidence of compound heterozygous DPYD variant allele carriers (of the four
genotyped DPYD variants), large databases were queried [32,33]. The incidence was calculated
using minor allele frequencies (MAFs) of each variant identified in the databases separately.
Since the determined variants are not in the same haplotype, it was assumed that the inheritance
of these individual DPYD variants is independent. All genotypes from the databases were
calculated to be in Hardy–Weinberg equilibrium, except for DPYD*2A and c.1236G>A for the Exome
Aggregation Consortium (ExAC, http://exac.broadinstitute.org/) [32] and Genome Aggregation
Database (gnomAD, http://gnomad.broadinstitute.org/) [33] due to a slight overrepresentation of
homozygous cases. The calculated frequencies were compared to frequencies from databases in which
phasing could be determined.
Exome Aggregation Consortium and Genome Aggregation Database
Both the ExAC [32] and gnomAD [33] databases collect exome sequencing data and aggregate the
data for public use. The ExAC dataset (v0.3.1) contains sequenced data of 60,706 unrelated individuals.
The gnomAD dataset (v2.0) contains sequenced data of 123,136 exomes and 15,496 genomes from
unrelated individuals. In ExAC, 2791 DPYD variants, and in gnomAD, 2190 DPYD variants were
found. MAFs of DPYD variants from these databases reflect those of the population due to the large
group size in the databases. Since both ExAC and gnomAD do not contain individual matched or
phased data, it is not possible to search for compound heterozygous patients in these databases.
2.5. Phasing in Compound Heterozygous DPYD Carriers
Three databases were used to identify compound heterozygous DPYD variant allele carriers and
determine the phasing, i.e., allelic location, of variants.
2.5.1. Genome of the Netherlands Datasets
The Genome of the Netherlands (GoNL, http://www.nlgenome.nl/) trio datasets contain
information of related fathers, mothers, and children, and phasing information is therefore available.
Datasets were previously processed and phased using trio-aware variant calling [34]. After the
exclusion of children, phased variant call format (VCF) files for 496 subjects (fathers and mothers) were
obtained from the GoNL repository. The toolset Bedtools (https://bedtools.readthedocs.io/en/latest/,
v2) was used to extract all variants found in the DPYD locus (chr1:97,543,300–98,386,615). Next, for all
individuals, the carrier status of DPYD*2A, DPYD*13, c.1236G>A, and c.2846A>T was examined.
Individuals who carry at least one of the four actionable DPYD variants were identified, and using a
custom Python [35] script, the phasing of variants was assessed for individuals with multiple variants.
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2.5.2. 1000 Genomes Database
The 1000 Genomes Project (http://www.internationalgenome.org/) is the largest publicly
available catalogue of human variation and genotyped phased data. It originally ran from 2008
until 2015, and thereafter it was maintained and expanded by the International Genome Sample
Resource (IGSR) [36]. On 27 October 2016, phased data of the DPYD gene (chr1: 97,543,300–98,386,615)
was downloaded from the 1000 Genomes ftp server (phase 3; GRCh37; chr1: 97,543,300–98,386,615)
using Tabix (v1.1) [37]. The statistical program R (v3.2.5) [38] was used to select the genotypes at four
DPYD risk alleles in unrelated individuals of Caucasian descent.
2.5.3. Exome Trios Leiden University Medical Centre Database
This diagnostic database of the clinical genetics department of LUMC contains 433 complete
exome trios (father, mother, and child). The exome was enriched by the Agilent sureselect v5 kit and
sequenced using various Illumina (San Diego, CA, USA) sequencers (Hiseq 2000, 2500, 4000, Nextseq).
Carrier status of the abovementioned DPYD variants was established by querying the trio VCF files.
We also investigated all samples with sufficient coverage of this region to obtain a reliable frequency
estimate. In the case of trios, only parents were taken into account.
3. Results
3.1. Patient Cases and Clinical Implications
Details of the demographics and clinical characteristics of the seven cases are described in the
supplementary material (patient cases). All patients received treatment with fluoropyrimidines and
were identified as compound heterozygous DPYD variant allele carriers either prior to the start of
treatment or retrospectively. Table 1 shows an overview of the cases. Table 2 shows all genotype and
phenotype results. With additional genetic testing, phasing could be determined in four out of seven
patients. In three patients, the variants were located in trans, and one patient carried the variants in cis.
With the phasing information available, it is possible to calculate a dose recommendation using publicly
available pharmacogenetic dosing guidelines [19,20]. For example, patient 1 carried DPYD*2A and
c.1236G>A in trans. The gene activity values range from inactive (0) to fully active (1). DPYD*2A and
c.1236G>A/HapB3 have values of 0 and 0.5, respectively. As this patient carries the variants in trans,
each allele contains one variant and no fully functional allele remains. Therefore, the cumulated gene
activity score (GAS) is 0.5. The GAS can be used to determine dose recommendations according to the
genotype, as was previously described [12]. The GAS ranges from 0 to 2, and a score of 0.5 corresponds
to a dose recommendation of 25%. The DPD enzyme activity of patient 1 was 0.9 nmol/(mg×h).
This was divided by the mean of the reference value (9.9), which results in a theoretical DPD activity of
9%. For each patient for whom phasing details were known, the GAS was determined and compared to
the theoretical DPD activity. Dose recommendations according to the GAS (genotype) and theoretical
DPD activity (phenotype) were divergent in almost all cases, as shown in Table 2.
3.2. Preventing Toxicity
Three of the seven case patients were identified as carriers of one or more DPYD variants prior
to the start of therapy. For one patient, the DPD enzyme activity was determined prior to the start
of therapy. Based on their genotype or phenotype, these three patients received initially reduced
fluoropyrimidine dosages of 50%. They experienced limited and reversible toxicity (CTC-AE grades
0–2). The dose of one patient was increased to 70% in the second treatment cycle, after which CTC-AE
grade 3 toxicity occurred.
Four of the seven case patients received a full dose, since their genotype was unknown prior to
the start of therapy. These patients all experienced severe toxicity (CTC-AE grades 3–5), and three
of them were admitted to the hospital for 7–14 days. An overview of cases, including the toxicity,
is shown in Table 3.
Genes 2018, 9, 585 6 of 13
3.3. Frequencies of Compound Heterozygous DPYD Carriers without Phasing Information
The ExAC and gnomAD databases revealed an average MAF for DPYD*2A, DPYD*13, c.1236G>A,
and c.2846A>T of 0.55%, 0.03%, 1.43%, and 0.27%, respectively. MAFs for ExAC and gnomAD
separately are summarized in Table 4. The probability of identifying a compound heterozygous DPYD
patient for two variants according to these databases was≤ 0.008%, as was calculated using frequencies
of combinations of DPYD variants. Results for each combination of DPYD variants are shown in
Table 5. With several million fluoropyrimidine users each year, thousands of patients worldwide are
compound heterozygous for a subset of these four DPYD variants.
3.4. Frequencies of Compound Heterozygous DPYD Carriers with Phasing Information
In the GoNL database, genetic data from 496 subjects (fathers and mothers only) was reviewed.
One subject was found who carried two DPYD variants. This subject was a carrier of the DPYD
c.1236G>A and DPYD c.2846A>T variants, both of which were located on a single allele (in cis). Based
upon the data in GoNL, the probability of having compound heterozygosity of the four DPYD variants
is <0.2%.
In the 1000 Genomes database, data of 2513 individuals were available. After the selection of
unique, unrelated individuals, 407 individuals remained. One subject was found who carried two
DPYD variants. This subject was a carrier of DPYD c.1236G>A and DPYD c.2846A>T, both of which
were located on different alleles (in trans). Based upon the data in 1000 Genomes, the probability of
having compound heterozygosity of the four DPYD variants is <0.3%.
In the LUMC clinical genetics database (exome trios LUMC), the analysis was restricted to the
children, since this would allow phasing. None of the 433 children carried more than one DPYD
variant, thus compound heterozygosity in this database is <0.2%.
Despite the low frequency, compound heterozygous patients were identified in all databases
except the LUMC clinical genetics database. However, the low frequency did not allow to determine
the probability of in cis or in trans phasing of variants in a patient.
Genes 2018, 9, 585 7 of 13
Table 1. Characteristics of patient cases. Shown per patient are primary tumor, treatment, capecitabine dose, executed assays (genotype, dihydropyrimidine
dehydrogenase (DPD) enzyme activity, and additional assays) information. Additional assays are droplet digital PCR, PacBio sequencing (Menlo Park, CA, USA),
or an in-house developed technique. For the executed assays, it is shown whether these were executed prior to treatment (P) or retrospectively (R). Abbreviations: BC:
breast cancer; CRC: colorectal cancer; CAP: capecitabine; RT: radiotherapy; OX: oxaliplatin; BEV: bevacizumab; bid: bis in die/twice a day.
Patient # Primary Tumor Treatment Capecitabine Dose Executed Assays
1 BC CAP 1000 mg/m2/bid Genotyping (R), DPD activity (R), in-house technique (R), droplet digital PCR (R)
2 BC CAP 800 mg bid (50%) Genotyping (P), DPD activity (R), in-house technique (R)
3 CRC CAP + OX 900 mg bid (50%) 1 Genotyping (P), DPD activity (P), PacBio (R)
4 BC CAP 1500 mg bid Genotyping (R), DPD activity (R 2)
5 CRC CAP + RT 800 mg bid (50%) Genotyping (P + R 3), DPD activity (R 4), PacBio (R)
6 CRC CAP + OX 1000 mg/m2/bid Genotyping (R), DPD activity (R)
7 CRC CAP + OX + BEV 1000 mg/m2/bid Genotyping (R), DPD activity (R)
1 Increased to 70% in the second cycle; 2 during hospital admission; 3 DPYD*2A was prospectively identified, c.2846A>T was retrospectively identified; 4 during treatment.
Table 2. Dose advice for compound heterozygous DPYD variant allele carriers. Shown per patient are DPYD variants, phasing of the DPYD variants, GAS,
retrospective DPWG dosing advice based on phasing, DPD enzyme activity, and percentage of DPD enzyme activity considered for dose advice. According to the
DPWG guidelines [19], a gene activity score can be given to compound heterozygous patients when phasing is known. Fully functional/reduced functionality
= gene activity score of 1.5; fully functional/inactive = gene activity score of 1; reduced functionality/reduced functionality = gene activity score of 1; reduced
functionality/inactive = gene activity score of 0.5; inactive/inactive = gene activity score of 0. Abbreviations: DPD: dihydropyrimidine dehydrogenase; GAS: gene
activity score; DPWG: Dutch Pharmacogenetic Working Group; X: could not be determined.
Patient # DPYD Variants Phasing GAS [12] DPWG Dose Advice(% of Regular Dose)
DPD Activity
(nmol/(mg×h)) Percentage of DPD Activity
1
1 DPYD*2A + c.1236G>A in trans 0.5 25% 0.9 9%
2 DPYD*2A + c.2846A>T in trans 0.5 25% 6.0 60%
3 c.1236G>A + c.2846A>T in trans 1 50% 4.5 45%
4 DPYD*2A + c.2846A>T unknown X X 0.11 1%
5 DPYD*2A + c.2846A>T in cis 1 50% 7.2 72%
6 DPYD*2A + c.1236G>A unknown X X 3.8 38%
7 DPYD*2A + c.1236G>A unknown X X 1.6 16%
1 The reference DPD activity ranges from 5.9–14 nmol/(mg×h) [28], and therefore the percentage of DPD activity can be calculated using the average of the reference (9.9 nmol/(mg×h).
This percentage could be used as a percentage of the regular dose.
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Table 3. Toxicity profiles of compound heterozygous DPYD variant allele carriers. Shown per patient are DPYD variants, fluoropyrimidine dose as a percentage of the
regular dose, and experienced toxicity with this dose. All patients retrospectively identified as DPYD variants carrier received full doses and experienced severe
(CTC-AE ≥ 3) toxicity. All patients prospectively identified as DPYD variant(s) carrier received dose reductions and experienced a maximum of CTC-AE grade 2
toxicity with the initial dose. Abbreviations: CTC-AE: Common Terminology Criteria for Adverse Events v4.03.
Patient # DPYD variants Dose (% of Regular Dose) Toxicity (Maximal CTC Grade)
1 DPYD*2A + c.1236G>A 100% 4
2 DPYD*2A + c.2846A>T 50% 1–2
3 c.1236G>A + c.2846A>T 50%→ 70% 0 (on 50% dose)→ 3 (on 70% dose)
4 DPYD*2A + c.2846A>T 100% 5
5 DPYD*2A + c.2846A>T 50% 0
6 DPYD*2A + c.1236G>A 100% 4
7 DPYD*2A + c.1236G>A 100% 3
Table 4. MAF per database. Three databases (GoNL, 1000 Genomes, and exome trios LUMC) containing phased data were checked for four DPYD variants. Two large
online databases (ExAC and gnomAD) were checked to identify the MAFs of the individual DPYD variants. For each DPYD variant, the genotype distribution and
MAF are shown. Abbreviations: MAF: minor allele frequency; HW: homozygous wild-type; HE: heterozygous carrier; HM: homozygous carrier; GoNL: Genome of the
Netherlands; ExAC: Exome Aggregation Consortium; gnomAD: Genome Aggregation Database.
Databases
Variants DPYD*2A (rs3918290) DPYD*13 (rs55886062) c.1236G>A (rs56038477) c.2846A>T (rs67376798)
HW/HE/HM MAF HW/HE/HM MAF HW/HE/HM MAF HW/HE/HM MAF
GoNL 489/7/0 0.7% 494/2/0 0.2% 475/21/0 2.1% 490/6/0 0.6%
1000 Genomes 405/2/0 0.2% 406/1/0 0.1% 389/18/0 2.2% 403/4/0 0.5%
Exome Trios LUMC 946/15/0 0.8% 946/0/0 0.00% 946/46/0 2.3% 946/2/0 0.1%
ExAC 60,627/624/5 0.5% 60,320/42/0 0.03% 60,652/1808/27 1.5% 60,687/317/1 0.3%
gnomAD 138,489/1586/10 0.6% 138,166/83/0 0.03% 138,407/3841/39 1.4% 138,478/792/1 0.3%
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Table 5. Calculated frequencies for compound heterozygous DPYD patients. Using the average MAFs
of the ExAC and gnomAD databases (for DPYD*2A, DPYD*13, c.1236G>A, and c.2846A>T, these are
0.55%, 0.03%, 1.43%, and 0.27%, respectively), possible combinations for two out of four currently
genotyped DPYD variants are shown. Abbreviations: MAF: minor allele frequency; ExAC: Exome
Aggregation Consortium; gnomAD: Genome Aggregation Database.
Combination of DPYD Variants Calculated Frequency
DPYD*2A + DPYD*13 0.0002%
DPYD*2A + c.1236G>A 0.008%
DPYD*2A + c.2846A>T 0.001%
DPYD*13 + c.1236G>A 0.0005%
DPYD*13 + c.2846A>T 0.0001%
c.1236G>A + c.2846A>T 0.004%
4. Discussion
Prospective genotyping of DPYD variants followed by individual dose adjustments is increasingly
applied as the standard of care for patients starting fluoropyrimidine therapy. Standard dose reductions
from CPIC and DPWG guidelines cannot be applied in patients who carry more than one DPYD
variant, as the phasing of the variants is unknown. Despite the low population frequency of < 0.2%,
the absolute number of identified compound heterozygous patients will increase as the number
of genotyped patients increases and the panel of tested variants is expanded. To the best of our
knowledge, this is the first study that describes a case series of compound heterozygous DPYD variant
allele carriers and investigates diagnostic and therapeutic strategies for these patients.
Our study shows the clinical need for further information on the genotype, as four patients
were identified as compound heterozygous carriers retrospectively and all of them experienced
severe toxicity. These compound heterozygous DPYD variant allele carriers have an increased
risk of developing severe fluoropyrimidine-induced toxicity if dosages are not adequately adjusted.
Previously, compound heterozygous patients have been described with severe or even lethal side effects
after fluoropyrimidine treatment [39,40]. Three patients in this study were prospectively identified as
compound heterozygous carriers, received initial dose reductions, and developed only mild toxicities.
Out of the four patients for whom we were able to retrieve phasing information, three were in
trans and one was in cis orientation. Data from publicly available databases also showed that both in
cis and in trans orientations exist. However, the recently updated CPIC guidelines on DPYD assumes
in trans phasing for compound heterozygous patients [20]. The DPWG guidelines do not mention
phasing; however, the dosing recommendations of the DPWG use the GAS, a score based on the
activity of individual alleles [19]. This implies the need for phasing information. The assumption
of in trans phasing could result in the underdosing of patients with variants phased in cis, and thus
exemplifies the need for the determination of the phasing of variants.
In this study, we looked at different diagnostic strategies to determine the phasing of DPYD
variants in compound heterozygous patients. In four patients, the phasing of DPYD variants could be
determined using one of three different molecular methods. These methods are in the early phases of
development, not routinely available, quite expensive, and not always conclusive. For two of these
techniques, patient RNA is used, which degrades quickly after the blood draw unless specifically
designed blood tubes are used. Compound heterozygous patients are rare, yet here we describe seven
patients heterozygous for multiple DPYD variants. A limitation of our study is that most patients
were identified retrospectively and in different institutions. Because of this, not enough of or not the
right material was available for analysis, thus not all genotyping techniques could be executed in
each patient. For two samples, tests failed or produced inconclusive results. For this reason, a formal
comparison of their suitability to identify phasing was not possible. However, of the three explored
molecular methods, PacBio sequencing seems most promising. While phasing improved the prediction
of DPD enzyme activity, patients with identical combinations of DPYD variants and identical phasing
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showed considerable differences in DPD enzyme activity, which could potentially limit the added
value of the determination of the phasing of DPYD variants. However, larger numbers of compound
heterozygous DPYD variant allele carriers would be necessary to draw a firm conclusion.
The measurement of DPD enzyme activity in PBMCs was used as a reference to assess DPD
activity. The method is well-established, commonly available, and shows limited intra- and interpatient
variability [27]. However, recently, differences in intrapatient variability in DPD enzyme activity related
to circadian rhythm were shown [41], which can result in the under- or overestimation of DPD enzyme
activity. In this study, we present one patient with extremely low DPD enzyme activity, which could
possibly be influenced by the presence of severe neutropenia, as DPD activity is normally measured in
mononuclear cells. Therefore, DPD enzyme activity can differ depending on the clinical condition of
the patient and should thus be measured prior to treatment.
A major question is whether genotyping or phenotyping is the best method to determine DPD
activity to guide fluoropyrimidine dosing in patients carrying multiple DPYD variants. Despite the
low population frequency, we present seven patients carrying multiple DPYD variants, of which
three received initially reduced fluoropyrimidine dosages. However, based on these data, it is
not possible to determine if a dose recommendation based on phased genetic information or
DPD enzyme activity measured in PBMCs is safer. In three out of four cases, differences were
observed between the theoretically calculated DPD activity using genotyping or phenotyping.
These differences would result in different dosing recommendations. For example, there is a
considerable interpatient variability in DPD enzyme activity in carriers of the DPYD variant
c.1236G>A/HapB3 [12]. Due to this variability, genetic dose recommendations are categorized
(e.g., 25 or 50%) on the average of the phenotypes. This categorization could explain the observed
dosing differences derived from genotyping and phenotyping. Other variants of DPYD currently
not routinely tested for or variants in other genes, e.g., MIR27A [42], might also be involved
in reducing DPD activity or explaining fluoropyrimidine-induced toxicity. DPD enzyme activity
measurements are well-established, and additional molecular methods to resolve phasing are still
in early phases of development. Therefore, in our opinion, the current therapeutic strategy for
compound heterozygous DPYD variant allele carriers should be to determine initial dose reductions
based on a DPD phenotyping test, for example, by measuring enzyme activity in PBMCs. Dosing
could be adjusted by the treating physician in subsequent cycles based on observed severe toxicity
(or lack thereof).
5. Conclusions
In conclusion, patients carrying multiple DPYD variants are at high risk of developing severe
toxicity. Additional analyses are required to determine the correct dose of fluoropyrimidine treatment.
In patients carrying multiple DPYD variants, we recommend that a DPD phenotyping assay be carried
out to determine a safe starting dose. The dose could be titrated in subsequent cycles based on
observed toxicity.
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